CA2676609A1 - Methods and compositions for treating neuropathies - Google Patents

Methods and compositions for treating neuropathies Download PDF

Info

Publication number
CA2676609A1
CA2676609A1 CA002676609A CA2676609A CA2676609A1 CA 2676609 A1 CA2676609 A1 CA 2676609A1 CA 002676609 A CA002676609 A CA 002676609A CA 2676609 A CA2676609 A CA 2676609A CA 2676609 A1 CA2676609 A1 CA 2676609A1
Authority
CA
Canada
Prior art keywords
activity
ampk
agent
nad
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002676609A
Other languages
English (en)
French (fr)
Inventor
Jeffrey Milbrandt
Biplab Dasgupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University
Jeffrey Milbrandt
Biplab Dasgupta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University, Jeffrey Milbrandt, Biplab Dasgupta filed Critical Washington University
Publication of CA2676609A1 publication Critical patent/CA2676609A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002676609A 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies Abandoned CA2676609A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88685407P 2007-01-26 2007-01-26
US60/886,854 2007-01-26
PCT/US2008/001085 WO2008091710A2 (en) 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies

Publications (1)

Publication Number Publication Date
CA2676609A1 true CA2676609A1 (en) 2008-07-31

Family

ID=39645095

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002676609A Abandoned CA2676609A1 (en) 2007-01-26 2008-01-28 Methods and compositions for treating neuropathies

Country Status (5)

Country Link
US (3) US20100047177A1 (3Den)
EP (1) EP2124985A4 (3Den)
CA (1) CA2676609A1 (3Den)
MX (1) MX2009008022A (3Den)
WO (1) WO2008091710A2 (3Den)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009221634B2 (en) 2008-03-03 2014-05-08 Nad Life Pty Ltd Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
EP2323649A4 (en) * 2008-07-25 2011-09-07 Univ Emory TREATMENT OF VARIOUS DISORDERS WITH 7,8-DIHYDROXY FLAVONE AND ITS DERIVATIVES
CN102369014A (zh) 2008-12-08 2012-03-07 西北大学 调节hsf-i的方法
JP2010215563A (ja) * 2009-03-17 2010-09-30 Kao Corp Ｌｋｂ１活性化剤
EP2579870B1 (en) 2010-06-09 2018-02-14 Emory University Trkb agonists and methods of use
CN102305863B (zh) * 2011-07-18 2013-11-20 厦门大学 以Nur77-LKB1相互作用为靶点的抗糖尿病药物筛选方法
EP2877461B1 (en) 2012-07-27 2018-05-09 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
EP4233878A1 (en) 2013-03-15 2023-08-30 Washington University Administration of nicotinamide mononucleotide in the treatment of dry eye
CN103877076B (zh) * 2014-03-21 2016-06-29 景临林 5,6,7,8-四羟基黄酮在制备抗缺氧药物中的应用
RU2016149767A (ru) 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
US10323058B2 (en) 2014-07-24 2019-06-18 W. R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
EP3268379B1 (en) 2015-03-09 2023-11-01 W.R. Grace & CO. - CONN. Crystalline form of nicotinamide riboside
US20170068860A1 (en) * 2015-09-09 2017-03-09 Alex Adekola System for measuring crowd density
WO2017201425A1 (en) * 2016-05-20 2017-11-23 The Trustees Columbia University In The City Of New York Anabolic enhancers for ameliorating neurodegeneration
CN112020363A (zh) 2017-12-22 2020-12-01 益力舒健康公司 烟酰胺核苷氯化物的结晶形式
JP2022523702A (ja) 2019-01-28 2022-04-26 ミトコンドリア エモーション， インク． トランス－４－ヒドロキシシクロヘキシルフェニルアミドマイトフュージン活性化物質及びその使用方法
WO2020159576A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
IT202000007726A1 (it) * 2020-04-10 2021-10-10 Solongevity Nutraceuticals S R L Composizioni mimetiche della restrizione calorica
CN114259486B (zh) * 2020-09-16 2024-04-02 香港科技大学 木犀草素及其药物组合物的应用
CA3208818A1 (en) * 2021-02-26 2022-09-01 Bo Chen A method for decreasing degeneration of retinal ganglion cells
EP4338798A1 (en) 2022-09-16 2024-03-20 Wasilewicz, Robert Henryk Pharmaceutical preparation containing genistein for use in the prevention or treatment of glaucoma and/or ocular hypertension

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055845A1 (en) * 1998-04-28 1999-11-04 Mitokor Cellular and animal models for diseases associated with altered mitochondrial function
US6001368A (en) * 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
IT1302365B1 (it) * 1998-10-09 2000-09-05 Sigma Tau Healthscience Spa Uso di carnitine e resveratrolo per produrre una composizione per laprevenzione o il trattamento terapeutico di alterazioni cerebrali
US6514719B1 (en) * 1999-05-28 2003-02-04 Immunex Corporation Methods for identifying compounds that alter kinase activity
US6573299B1 (en) * 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
US6821775B1 (en) * 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20050080024A1 (en) * 2002-08-15 2005-04-14 Joseph Tucker Nitric oxide donating derivatives for the treatment of cardiovascular disorders
US7320806B2 (en) * 2002-09-09 2008-01-22 Vdf Futureceuticals, Inc. Compositions and methods for treating NIDDM and other conditions and disorders associated with AMPK regulation
GB2402938B (en) * 2003-06-17 2005-11-09 Medical Res Council Kinase assay
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
US20070105109A1 (en) * 2003-07-02 2007-05-10 Geesaman Bard J Sirt1 and genetic disorders
AU2004312072B2 (en) * 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2555675A1 (en) * 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
US20050227327A1 (en) * 2004-02-10 2005-10-13 Brenner Charles M Nicotinamide riboside kinase compositions and methods for using the same
WO2006001982A2 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies
US20060035302A1 (en) * 2004-06-21 2006-02-16 Applera Corporation Kinase substrates with multiple phosphorylation sites
WO2006001278A1 (ja) * 2004-06-28 2006-01-05 Kao Corporation Ａｍｐｋ活性化剤
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
AU2006269459B2 (en) * 2005-07-07 2013-02-07 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2617557A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
MY154869A (en) * 2007-01-16 2015-08-14 Ipintl Llc Composition for treating metabolic syndrome

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof

Also Published As

Publication number Publication date
MX2009008022A (es) 2009-12-11
WO2008091710A3 (en) 2008-10-09
WO2008091710A2 (en) 2008-07-31
EP2124985A4 (en) 2011-06-08
EP2124985A2 (en) 2009-12-02
US20140011890A1 (en) 2014-01-09
US20100047177A1 (en) 2010-02-25
US20160367497A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
US20160367497A1 (en) Methods and compositions for treating neuropathies
EP3006040B1 (en) Methods and compositions for treating neuropathies
Hurtado et al. Citicoline (CDP‐choline) increases S irtuin1 expression concomitant to neuroprotection in experimental stroke
Jimenez‐Pacheco et al. Increased neocortical expression of the P 2X7 receptor after status epilepticus and anticonvulsant effect of P 2X7 receptor antagonist A‐438079
Barahona et al. Glial hypothalamic inhibition of GLUT2 expression alters satiety, impacting eating behavior
Sharma et al. Circadian rhythm disruption and Alzheimer’s disease: the dynamics of a vicious cycle
Chen et al. Calcineurin β protects brain after injury by activating the unfolded protein response
US20100266569A1 (en) Prostatic acid phosphatase for the treatment of pain
Mohammad-Gharibani et al. Mode of action of S-methyl-N, N-diethylthiocarbamate sulfoxide (DETC-MeSO) as a novel therapy for stroke in a rat model
T Hansen III et al. Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfalls
Tseng et al. Tau seeds are subject to aberrant modifications resulting in distinct signatures
JP2007528202A (ja) 神経再生のための組成物および方法
Link et al. Membrane localization of all class I PI 3‐kinase isoforms suppresses c‐Myc‐induced apoptosis in Rat1 fibroblasts via Akt
Yao et al. Polycystin-1 dependent regulation of polycystin-2 via GRP94, a member of HSP90 family that resides in the endoplasmic reticulum
ES2385157B1 (es) Compuestos para el tratamiento de alzheimer.
Kanungo et al. Cloning and characterization of zebrafish (Danio rerio) cyclin-dependent kinase 5
Balczon et al. Infection promotes Ser‐214 phosphorylation important for generation of cytotoxic tau variants
de Talhouët et al. KAT8 compound inhibition inhibits the initial steps of PINK1-dependant mitophagy
Medici New insight into CDKL5 deficiency disorder pathomechanism: phosphoproteomic profiling identifies SMAD3 as a novel downstream target of CDKL5
Li Investigating the neuroprotective role of OGA inhibition by Thiamet-G against Alzheimer\'s disease
JP5670921B2 (ja) 神経突起伸長阻害の軽減のためのプロテインキナーゼａ及び／又はカゼインキナーゼｉｉ
Hurtado Moreno et al. Citicoline (CDP-choline) increases Sirtuin1 expression concomitant to neuroprotection in experimental stroke
Alabed The role of RhoA interacting proteins in the Nogo signalling pathway of axon outgrowth inhibition

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130128

FZDE Discontinued

Effective date: 20170804